Business & Finance
Recipharm swings to loss in 2017
23 February 2018 -

Recipharm AB (STO:RECIB), a Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry, on Thursday reported loss after tax of SEK160m, or SEK2.70 per diluted share, for 2017.

This was a decline over profit after tax of SEK196m, or diluted EPS or SEK3.32, for 2016.

Net sales for the year amounted to SEK5,332m, up by 14.0% as compared with SEK4,678m in 2016.

Also, the company's board of director has proposed that no dividend will be paid for 2017, as compared with SEK1.50 per share in 2016.

Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development.